To my X followers, including the fake and catfish accounts: For some time I have been the target of sustained personal harassment on this platform, much of it from anonymous and impersonating accounts. I have stayed quiet and kept working. I am addressing it now, once, and then returning to the science. I am not the only one. A number of researchers working on the biological basis of this illness, including collaborators of mine, have faced the same pattern of harassment. Much of it appears coordinated and comes from a small number of accounts whose interest is clearly not the science: their aim is not scientific debate; it is to intimidate people for doing research they do not like. Targeting scientists for studying a disease is not scepticism; it is intimidation. On the facts: the claim that our work "has not been replicated" is untrue. Independent groups have confirmed or applied these findings: - the same aggregates were confirmed in pulmonary embolism (Baker et al., Communications Medicine, 2023); - amyloid-fibrinogen aggregates predicted disseminated intravascular coagulation and mortality in sepsis (Schofield/Toh et al., Blood Advances, 2024); -increased fibrinaloid microclots were found in Long COVID by an independent UK group (Dalton et al., Sheffield Hallam, preprint, 2024); - and the methods have been taken up in paediatric Long COVID (Steifman, Yonker et al., Pediatric Research, 2026). This is now a field with dozens of independent papers. One thing to make very clear: I have no involvement in any apheresis or plasmapheresis treatment for these conditions. Why? It is simply not my field of expertise. I cannot control how others use published methods, and it is wrong to attribute their choices to me. On Biocode, our start-up company: public universities have a clear responsibility to translate research into public benefit, and commercialising discoveries through spin-out companies is a core part of that mandate. That is precisely what Biocode was created to do. It is an early-stage university spin-out, it is not profitable, and repeated insinuations that I am personally enriching myself are false. I welcome robust scientific criticism; that is how science works, and II have actively reached out to colleagues who see the field differently. Harassment, account stalking, impersonation and personal attacks are not criticism. I am documenting it, I am taking advice on my options, and I will not be engaging with it further. Just because biological researchers are targeted in this way does not mean we will stop. If anything, it strengthens our resolve to understand diseases and to serve the millions of patients who are waiting for answers.